Resumen
The prevalence of cardiovascular disease (CVD) in antiphospholipid syndrome (APS) varies from one series to another depending on the definition of CVD and tools used for its detection. Atherosclerosis, the usual cause of CVD, starts when the endothelium becomes damaged and is considered to be an autoimmune-inflammatory disease. The excessive cardiovascular events observed in patients with APS are not fully explained by traditional risk factors. Therefore, several novel risk factors contribute to the development of premature CVD and accelerated vascular damage in those patients. Herein, the significance and outcomes of CVD in APS are reviewed.
| Idioma original | Inglés estadounidense |
|---|---|
| Páginas (desde-hasta) | 1288-1291 |
| Número de páginas | 4 |
| Publicación | Lupus |
| Volumen | 23 |
| N.º | 12 |
| DOI | |
| Estado | Publicada - oct 8 2014 |
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
-
ODS 3: Salud y bienestar
Áreas temáticas de ASJC Scopus
- Reumatología
Huella
Profundice en los temas de investigación de 'Cardiovascular disease in the antiphospholipid syndrome'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver